148 related articles for article (PubMed ID: 17465259)
1. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma.
Kim MS; Cho WH; Song WS; Lee SY; Jeon DG
Anticancer Res; 2007; 27(2):1171-8. PubMed ID: 17465259
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas.
Weng WH; Ahlén J; Aström K; Lui WO; Larsson C
Clin Cancer Res; 2005 Sep; 11(17):6198-204. PubMed ID: 16144921
[TBL] [Abstract][Full Text] [Related]
3. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma.
Hsu HC; Huang EY; Wang CJ
Acta Oncol; 2004; 43(6):530-5. PubMed ID: 15370609
[TBL] [Abstract][Full Text] [Related]
4. [An analysis of prognostic factors for malignant fibrous histiocytoma of bone].
Li GX; Guo W; Yang RL; Qu HY; Tang S; Qi DW
Zhonghua Wai Ke Za Zhi; 2011 Aug; 49(8):733-6. PubMed ID: 22168940
[TBL] [Abstract][Full Text] [Related]
5. Primary malignant fibrous histiocytoma (myxofibrosarcoma/pleomorphic sarcoma not otherwise specified) of the breast: clinicopathologic study of 19 cases.
Hartel PH; Bratthauer G; Hartel JV; Fanburg-Smith JC
Ann Diagn Pathol; 2011 Dec; 15(6):407-13. PubMed ID: 21983422
[TBL] [Abstract][Full Text] [Related]
6. Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas.
Carneiro A; Bendahl PO; Åkerman M; Domanski HA; Rydholm A; Engellau J; Nilbert M
J Clin Pathol; 2011 Aug; 64(8):689-94. PubMed ID: 21653656
[TBL] [Abstract][Full Text] [Related]
7. Primary hepatic malignant fibrous histiocytoma: clinicopathologic characteristics and prognostic value of ezrin expression.
Li YR; Akbari E; Tretiakova MS; Hart J; Akbari M; Urbanski SJ; Gao ZH
Am J Surg Pathol; 2008 Aug; 32(8):1144-58. PubMed ID: 18545143
[TBL] [Abstract][Full Text] [Related]
8. Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.
Gu J; Zhang S; Wu X; Shi J; Zhang B; Zhang X; Yang J; Obulkasim H; Duan F; Deng C; He J; Zou X; Ding Y
Int J Clin Exp Pathol; 2015; 8(3):2876-87. PubMed ID: 26045796
[TBL] [Abstract][Full Text] [Related]
9. iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis.
Hoki Y; Hiraku Y; Ma N; Murata M; Matsumine A; Nagahama M; Shintani K; Uchida A; Kawanishi S
Cancer Sci; 2007 Feb; 98(2):163-8. PubMed ID: 17233833
[TBL] [Abstract][Full Text] [Related]
10. [Malignant fibrous histiocytoma of the retroperitoneum--review of clinical course and histopathology].
Ichihara K; Takahashi S; Takahashi A; Masumori N; Itoh N; Hasegawa T; Takagi Y; Taguchi K; Tsukamoto T
Hinyokika Kiyo; 2006 Oct; 52(10):761-4. PubMed ID: 17131862
[TBL] [Abstract][Full Text] [Related]
11. The outcome of pleomorphic sarcoma at University Malaya Medical Center--a fifteen-year review.
Chan CY; Janarthan N; Vivek AS; Jayalakshmi P
Med J Malaysia; 2008 Oct; 63(4):311-4. PubMed ID: 19385491
[TBL] [Abstract][Full Text] [Related]
12. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
14. Malignant fibrous histiocytoma of the sinonasal tract.
Wang CP; Chang YL; Ting LL; Yang TL; Ko JY; Lou PJ
Head Neck; 2009 Jan; 31(1):85-93. PubMed ID: 18853446
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
16. Histological vascular invasion by tumors is a risk factor for distant metastasis in malignant fibrous histiocytoma.
Yonemoto T; Tatezaki S; Ishii T; Iwata S; Takeuchi Y; Araki A
Anticancer Res; 2005; 25(2B):1337-42. PubMed ID: 15865088
[TBL] [Abstract][Full Text] [Related]
17. Primary malignant fibrous histiocytoma of the lung.
Rzyman W; Jaskiewicz K; Murawski M; Sternau A; Marjanski T; Karmolinski A; Dziadziuszko R
Thorac Cardiovasc Surg; 2007 Apr; 55(3):186-9. PubMed ID: 17410507
[TBL] [Abstract][Full Text] [Related]
18. Expression profiles in malignant fibrous histiocytomas: clues for differentiating 'spindle cell' and 'pleomorphic' subtypes.
Scapolan M; Perin T; Wassermann B; Canzonieri V; Colombatti A; Italia F; Spessotto P
Eur J Cancer; 2008 Jan; 44(2):298-309. PubMed ID: 18054831
[TBL] [Abstract][Full Text] [Related]
19. [Malignant fibrous histiocytoma of the bladder. A literature review].
Povo-Martín I; Gallego-Vilar D; Bosquet-Sanz M; Miralles-Aguado J; Gimeno-Argente V; Rodrigo-Aliaga M; Gallego-Gómez J
Actas Urol Esp; 2010 Apr; 34(4):378-85. PubMed ID: 20470701
[TBL] [Abstract][Full Text] [Related]
20. Survival analysis of malignant melanoma in Japan--multivariate analysis of prognostic factors.
Uehara S; Kamo R; Harada T; Ishii M
Osaka City Med J; 2009 Jun; 55(1):35-52. PubMed ID: 19725433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
